tbuckley/cabot-search huggingface dataset:
AB0066 Treatment of rheumatoid arthritis with leflunomide
Authors: M Castellanos, N Navarro, MC García, C Galisteo, M Sanmartí, MP Lisbona, C Alegre
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To study the clinical efficacy and safety for the treatment in patients with rheumatoid arthritis (RA) with Leflunomide. <h3>Methods</h3> We included 15 patients with diagnostic of the RA according to American College of Rheumatology (ACR) criterias for at least 6 months and active disease by the following inclusion criteria: &gt; 18 years old, &gt; 6 tender and swollen joints, &gt; 15 mg/dl C-reactive protein (CRP), &gt; 28 mm/h erythrocyte sedimentation rate (ESR) and morning stiffness. We treated with Leflunomide loading dose 100 mg/day for 3 days, and after we continued with 20 mg/day. The clinical controls were the first and the end of a period of time, 26 weeks: general examination (weight, arterial pressure, morning stiffness), locomotor system (tender and swollen joint count score), acute- phase reactant (PCR, ESR) inmunology (ANA, anti-DNA, FR, C3, C4) hepatic serologies, simple radiography study (thorax, hands and feet). Evaluation of patients with a general pain, analogic visual (EVA) and the Stanford Healt Assessment Questionaire (HAQ). Non steroidal antiinflamatories drugs and steroids were allowed provided the subject had been receiving a continuous dose for at least 28 days prior to entry in the study. Intra-articular corticosteroid were not allowed. <h3>Results</h3> The 15 patients 3 are men and 12 women, with a mean age of 68 years. After 3 months, the mean changes were -6.9 swollen joints, -10.4 tender joints, -44.8 for ESR, -26 for CRP. The most common adverse events with this treatment were three: one cutaneous allergic reaction (in this case was necessary stopping the treatment) and 2 diarrhoea. In one case the clinical was disappear after reducing in 10 mg/day, and the other it should interrupt the treatment. <h3>Conclusion</h3> Leflunomide seems to be efficacious and safety for treatment in RA. Every way, must follow evaluation for a long time to recommend treatment like a first election.
‘I’m asking you to believe—not in my ability to create change, but in yours’: four strategies to enhance patients’ rehabilitation adherence
Authors: Adam Gledhill, Dale Forsdyke, Tom Goom
Journal: British Journal of Sports Medicine (2020)

‘I’m asking you to believe—not in my ability to create change, but in yours.’ Former US President Barack Obama provides a poignant message for sport and exercise medicine clinicians that relates to rehabilitation adherence (‘adherence’ in this paper): patients have to be their own agent of change; we can not do it for them.

At a time when patients can experience negative psychosocial and emotional responses to injury, their emotional integrity (eg, the honesty of information they share with their treating clinicians) and their ability to make rational decisions can be compromised.1 Think about your own practice; how many times have you had a conversation similar to that in box 1. We know that patients’ home and clinic-based adherence rates are often poor.2 Helping to improve adherence is important as it is associated with better return to sport (RTS) outcomes.3 Therefore, the aims of this editorial are to (a) provide psychologically informed suggestions that can enhance adherence and (b) based on principles of best evidence-synthesis, provide theoretical or empirical underpinning to these suggestions.

Box 1 
### Example conversation between clinician and patient

Clinician: ‘Hi there. How are you doing today?’

Patient: ‘Good, thanks’

Clinician: ‘That’s great! Has the injury improved?’

Patient:   ‘No, not really’

Clinician: ‘Oh, that’s too bad. …
SAT0135 Association between hepatitis c virus antibody, hepatitis b virus antigen and fibromiyalgia
Authors: A Gür, M Karakoç, MF Geyik, K Nas, R Çevik, AJ Saraç, S Em, F Erdogan
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Although Hepatitis B virus and hepatitis C virus infections have been associated with several autoantibodies, the relationship between HCV, HBV infections and autoimmun response and autoimmune diseases remains unknown. In the literature there are suspectible results related to antibody positivity against HCV and antigen positivity HBV in cases with fibromiyalgia syndrome and rheumatoid arthritis. <h3>Objectives</h3> The objective was to determine whether there might be association between HBs-Ag, anti-HCV and fibromyalgia. <h3>Methods</h3> We determined the prevalence of Anti-HCV, in 51 fibromiyalgia patients, in comparison 35 rheumatoid arthritis patients from the Dicle University Hospital. <h3>Results</h3> Among 51 patients with fibromyalgia, we detected 10 patients (19.6%) with HBs-Ag and 1 (1.96%) anti-HCV antibody, whereas we found no HBs-Ag and anti-HCV antibody among in all of the rheumatoid arthritis cases. We found statistically significant difference when we compared the HBs-Ag positivity established in fibromiyalgia cases with those in healthy blood donors (which is found to be 4.87% in our region) and cases with rheumatoid arthritis (p &lt; 0.05). Also, there was not any difference in terms of anti-HCV antibody positivity between the fibromiyalgia and rheumatoid arthritis, healthy blood donors (p &gt; 0.05). <h3>Conclusion</h3> In conclusion, our study suggest that there may exist an association between fibromiyalgia and HBs-Ag. In addition, our data do not support the hypothesis that HCV infection may play a role in the pathogenesis of fibromyalgia.
EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort
Authors: Prashasti Agrawal, Kevin A. David, Zhengming Chen, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary-Kate Malecek, Jordan Carter, Adam Zayac, Myung Sun Kim, Nishitha Reddy, Alma Habib, Christopher Strouse, Jerome Graber, Veronika Bachanova, Mazie Tsang, Ajay Major, David A. Bond, Angel Mier-Hicks, Pallawi Torka, Priya Rajakumar, Parameswaran Venugopal, Michael Glantz, Samuel Goldlust, Rahul Matnani, Pallavi Kumar, Thomas A Ollila, Johnny Cai, Stephen E. Spurgeon, Alex G Sieg, Joseph Cleveland, Narendranath Epperla, Reem Karmali, Seema Naik, Sonali M. Smith, James L. Rubenstein, Brad S. Kahl, Amy Chadburn, Andrew M. Evens, Peter Martin
Journal: Blood (2020)
Abstract 17501: Cardiomyocyte Regulates Cardiac Fibrosis through Cell to Cell Interaction Mediated by KLF6
Authors: Daigo Sawaki, Toru Suzuki, Kenichi Aizawa, Takayoshi Matsumura, Yoshiko Munemasa, Junichi Ishida, Scott Friedman, Ryozo Nagai
Journal: Circulation (2012)

Introduction: Previous studies suggest that Kruppel-like factors (KLFs) play important roles in the cardiovasculature. We had previously identified and cloned KLF6, whose homozygous mutation in mi...
Is the peritoneal lavage cytology coincided with peritoneal metastasis for gastric cancer?
Authors: Wei Wang, Wenjun Xiong, Yaohui Peng, Jin Li, Haipeng Huang, Yansheng Zheng, Lijie Luo, Jin Wan
Journal: Journal of Clinical Oncology (2020)

e16533 Background: Gastric cancer (GC) with peritoneal metastasis (PM) is associated with a poor prognosis. The free cancer cells are the prerequisite of peritoneal metastasis. Peritoneal lavage cytology (PLC) is the main measure to identify the free cancer cells, but its positive rate is relatively low. This study aims to investigate the association between the result PLC and peritoneal metastasis for GC. Methods: From November 2017 to December 2019, 33 patients with GC were confirmed with PM through computerized tomography or diagnostic laparoscopy. The inflow and outflow catheters were inserted laparoscopically in all patients for postoperative hyperthermic intraperitoneal chemotherapy. PLC was performed with at least 200 ml of fluid and examined by measures of cytology and immunocytopathology. Ascites was aspirated if detected or 500 milliliter of normal saline infused the Douglas cavity, para-colic gutters and the right and left sub-phrenic cavity and then aspirated. Results: There were 15 males and 18 females and the median age was 56 (24-84) years old. All patients had a cT4a/cT4b and an N-positive tumor. The overall positive PLC (PLC+) rate was 63.6% (21/33). The distribution of Lauren classification was respectively 5 (15.2%) intestinal, 26 (78.8%) diffused and 2 (6.1%) mixed tumor. The diffused cases had a higher rate of PLC+ ( P = 0.004). All 5 intestinal GC had a negative PLC (PLC-). 71.4% (20/28) of patients with a grade G3/G4 had a PLC+, compared, no PLC+ was recorded in 5 grade G1/G2 patients (P = 0.003). The median peritoneal carcinomatosis index (PCI) was 14 (1-39). The PLC+ rate was 94.7% (18/19) in PCI &gt; = 10 group and 21.4% (3/14) in PCI &lt; 10 group ( P &lt; 0.001). The median ascites was 200 (0-7000) ml. The PLC+ rate was 88.2% 15/17) in ascites &gt; = 200 ml group and 37.5% (6/16) in ascites &lt; 10 ml ( P = 0.002). The median follow-up was 13(1-27) months and the overall survival was 75.8%, but no significance was detected between PLC+ group and PLC- group. Conclusions: The present study suggested that the result of PLC was not completely coincided with PM for GC by measures of cytology and immunocytopathology, especially for intestinal and grade G1/G2 tumor.
Abstract PO-075: Dysfunction of centrosome regulation by BRCA1-containing complex increases tumor heterogeneity
Authors: Natsuko Chiba
Journal: Cancer Research (2020)

Abstract Centrosomes are the major microtubule-organizing centers in animal cells and are critical for the formation of a bipolar mitotic spindle. Alterations in centrosome number and structure often occur together and are associated with many cancers. Centrosome aberrations results in chromosome segregation errors and abnormal cell division, leading to chromosomal instability (CIN). CIN is a major source of aneuploidy, resulting in tumor heterogeneity. Centrosome aberrations are observed in the early stages of tumorigenesis and are correlated with CIN. Breast cancer gene 1 (BRCA1) is a tumor suppressor that is associated with hereditary breast and ovarian cancer. Functions of BRCA1 in DNA repair, especially homologous recombination, has been focused, whereas BRCA1 regulates centrosome together with BRCA1-associated RING domain protein (BARD1). We identified BRCA1-interacting proteins, Obg-like ATPase 1 (OLA1) and receptor for activated C kinase (RACK1). OLA1 and RACK1 directly bound to BRCA1, BARD1, and γ-tubulin and localized the centrosomes throughout the cell cycle. Overexpression of OLA1 or RACK1 caused centrosome amplification due to centriole overduplication in mammary tissue-derived cells. The number of centrioles in cells was higher in cell lines derived from mammary tissue compared to those derived from other tissues. Knockdown of RACK1 caused abnormal centrosomal localization of BRCA1 and abrogated centriole duplication. Overexpression of RACK1 increased the centrosomal localization of BRCA1. Cancer-derived variants of BRCA1, BARD1, OLA1, and RACK1 abolished or weakened their interaction and function in centrosome duplication. These data suggest that the formation of BRCA1/BARD1/OLA1/RACK1 complex is important for centrosome regulation to maintain genome stability and that dysfunction of this complex will increase tumor heterogeneity that associated with carcinogenesis and cancer progression. Citation Format: Natsuko Chiba. Dysfunction of centrosome regulation by BRCA1-containing complex increases tumor heterogeneity [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-075.
Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL)
Authors: Georgios Christopoulos, Zachi I. Attia, Peter A. Noseworthy, Timothy G. Call, Wei Ding, Jose F. Leis, Eli Muchtar, Saad S. Kenderian, Yucai Wang, Amber Koehler, Neil E. Kay, Prashant Kapoor, Paul A. Friedman, Joerg Herrmann, Sameer A. Parikh
Journal: Blood (2020)
Minimal Residual Disease (MRD) at 10-6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication<i>)</i>
Authors: Alessandro Gozzetti, Donatella Raspadori, Paola Pacelli, Elisabetta Antonioli, Elena Bestoso, Sara Ciofini, Francesca Bacchiarri, Gabriele Buda, Dania Tocci, Cristiana Cafarelli, Anna Marina Liberati, Piero Galieni, Giulia Lucco Navei, Ubaldo Occhini, Anna Sicuranza, Michela Staderini, Rosaria Crupi, Mario Petrini, Alberto Bosi, Monica Bocchia
Journal: Blood (2020)
Abstract MP154: Deletion of the Duffy Antigen Receptor for Chemokines (DARC) Confers Protection Against Abdominal Aortic Aneurysm (AAA) Formation
Authors: Tyler W Benson, Tetsuo Horimatsu, Mourad Ogbi, Ha Won W Kim, Neal L Weintraub
Journal: Circulation Research (2020)

Introduction: Abdominal aortic aneurysms (AAA) are characterized by inflammation and matrix metalloproteinase (MMP)-mediated degradation of extra cellular matrix proteins leading to aortic dilation and potentially rupture. Inflammatory chemokines that promote AAA are modulated by binding to the Duffy antigen receptor for chemokines (DARC), a non-signaling receptor expressed primarily on erythrocytes. Interestingly, African Americans exhibit reduced frequency of AAA, and the majority of African descendent individuals do not express DARC on their erythrocytes. Here, we tested the hypothesis that DARC gene deletion protects against the development of AAA. Methods: The induction of AAA was performed using both angiotensin II (AngII) infusion and calcium chloride (CaCl 2 ) application models. Eight week old LDLR knockout (KO, control) and LDLR KO/DARC KO mice were infused with AngII via osmotic mini-pumps for four weeks. For the CaCl 2 application model, twelve week old DARC KO and WT control mice underwent laparotomy and 0.5 mol/L CaCl 2 was applied to the infrarenal aorta. Aortic dilation and AAA formation was assessed using ultrasound, mice were then euthanized and tissues were harvested for analysis. Results: The aortic diameter of LDLR KO/DARC KO mice was significantly lower relative to control mice after AngII infusion (P=0.02). There was no difference in the pressor response to AngII between groups. Furthermore, IL-6 levels were significantly reduced in the aortas of LDLR KO/DARC KO mice compared to control mice (P=0.001). Expression of MCP-1, which has strong affinity for DARC, tended to be higher in aortas from LDLR KO/DARC KO mice compared to control (P=0.063). In contrast, plasma IL-6 levels were similar in both LDLR KO/DARC KO and control mice, while MCP-1 tended to be lower in the plasma of LDLR KO/DARC KO (P=0.07). DARC KO mice likewise exhibited a trend toward reduced aortic dilation in the CaCl 2 application model compared to controls (P=0.09). Conclusions: DARC KO mice are protected against AAA formation, perhaps through differential regulation of aortic chemokine trafficking. Understanding the mechanisms by which loss of DARC confers protection from AAA formation may be relevant to ethnic differences in susceptibility to AAA.
Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin Lymphoma (HL) at Children's Oncology Group (COG) Institutions
Authors: Sharon M. Castellino, Angela Punnett, Susan K Parsons, Nicholas P. DeGroote, Sally Muehle, Hongli Li, Michael E. Roth, Alex F. Herrera, Jonathan W. Friedberg, Nita L. Seibel, Kara M. Kelly
Journal: Blood (2020)
Abstract 485: Mito-Targeted Antioxidant Superior to Non-Targeted Isoform in Modulating Energy Metabolism and Preventing Cardiovascular Remodelling in Spontaneously Hypertensive Rat
Authors: Sherin Saheera, Ajay Godwin Potnuri, Raunak R Nair
Journal: Circulation Research (2020)

Hypertension induced left ventricular hypertrophy (LVH) augments the risk of cardiovascular anomalies. Oxidative stress leads to the activation of the hypertrophic program with a metabolic switch from fatty acid to glucose oxidation. Mitochondria, the major source of free radicals, exhibit alterations in hypertensive heart diseases. Targeted antioxidants are expected to reduce mitochondrial reactive oxygen species more effectively than general antioxidants. This study was designed to assess whether mito-targeted antioxidant, MitoTempol is more effective than general oxidant, Tempol on hypertension, hypertrophy and cardiac energy metabolism. Spontaneously Hypertensive Rat were administered either Tempol (20mg/kg/day) or Mito Tempol (2mg/kg/day) orally for 30 days. Post treatment, animals were subjected to 2D-echocardiography. The Myocardial lysates were subjected to Insolution digestion followed by RPLC - LTQ-Orbitrap-MS analysis. Mid-ventricular sections were probed for markers of energy metabolism and fibrosis. The beneficial effect on cardiovascular structure and function was significantly higher for Mito Tempol. Increase in mitochondrial antioxidants and stimulation of fatty acid metabolism with significant improvement in cardiovascular function was apparent in SHR treated with Mito Tempol. The study indicates that Mito Tempol is superior to its non- targeted isoform in preventing hypertension induced LVH, and the beneficial effects on heart are possibly mediated by reversal of metabolic remodelling.
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases
Authors: Xiaolin Wang, Yong He, Bryan Mackowiak, Bin Gao
Journal: Gut (2020)

MicroRNAs (miRNAs) are small, non-coding RNAs that post-transcriptionally regulate gene expression by binding to specific mRNA targets and promoting their degradation and/or translational inhibition. miRNAs regulate both physiological and pathological liver functions. Altered expression of miRNAs is associated with liver metabolism dysregulation, liver injury, liver fibrosis and tumour development, making miRNAs attractive therapeutic strategies for the diagnosis and treatment of liver diseases. Here, we review recent advances regarding the regulation and function of miRNAs in liver diseases with a major focus on miRNAs that are specifically expressed or enriched in hepatocytes (miR-122, miR-194/192), neutrophils (miR-223), hepatic stellate cells (miR-29), immune cells (miR-155) and in circulation (miR-21). The functions and target genes of these miRNAs are emphasised in alcohol-associated liver disease, non-alcoholic fatty liver disease, drug-induced liver injury, viral hepatitis and hepatocellular carcinoma, as well liver fibrosis and liver failure. We touch on the roles of miRNAs in intercellular communication between hepatocytes and other types of cells via extracellular vesicles in the pathogenesis of liver diseases. We provide perspective on the application of miRNAs as biomarkers for early diagnosis, prognosis and assessment of liver diseases and discuss the challenges in miRNA-based therapy for liver diseases. Further investigation of miRNAs in the liver will help us better understand the pathogeneses of liver diseases and may identify biomarkers and therapeutic targets for liver diseases in the future.
Outcomes of <i>IDH1</i>- and <i>IDH2</i>-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Authors: Evan C. Chen, Shuli Li, Ann-Kathrin Eisfeld, Marlise R Luskin, Alice S. Mims, Daniel Jones, Joseph H. Antin, Corey Cutler, John Koreth, Vincent T. Ho, Mahasweta Gooptu, Rizwan Romee, Areej El-Jawahri, Steven L. McAfee, Zachariah Defilipp, Robert J. Soiffer, Yi-Bin Chen, Amir T. Fathi
Journal: Blood (2020)
Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)
Authors: Yasuyoshi Morita, Takayuki Ikezoe, Kiyoshi Ando, Masahiro Onozawa, Takahisa Yamane, Naoko Hosono, Toru Kiguchi, Hiromi Iwasaki, Toshihiro Miyamoto, Miho Kasai, Saori Sugimoto, Yasushi Miyazaki, Masahiro Kizaki, Koichi Akashi
Journal: Blood (2020)
First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Authors: Niels W.C.J. van de Donk, Rakesh Popat, Jeremy Larsen, Monique C. Minnema, Sundar Jagannath, Albert Oriol, Jeffrey Zonder, Paul G. Richardson, Paula Rodriguez-Otero, Ashraf Z. Badros, Edward Stadtmauer, Sara Bringhen, Erica Campagnaro, David S. Siegel, Barbara Gamberi, Mercedes Gironella Mesa, Pieter Sonneveld, Tuong Vi Nguyen, Antonia Di Micco, April Sorrell, Min Chen, Michael Amatangelo, Elisabeth Kueenburg, Sagar Lonial
Journal: Blood (2020)
The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma
Authors: Sunyoung Lee, Kyoung Won Kim, Gi-Won Song, Jae Hyun Kwon, Shin Hwang, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Gil-Chun Park, Sung-Gyu Lee
Journal: Liver Cancer (2020)

There is no consensus regarding selection criteria on liver transplantation (LT) for hepatocellular carcinoma (HCC), especially for living donor liver transplantation, although emerging evidence has been found for the effectiveness of bridging or downstaging.We evaluated the long-term outcomes of patients who underwent LT with or without bridging or downstaging for HCC.This retrospective study included 896 LT recipients with HCC between June 2005 and May 2015. Recurrence-free survival (RFS), overall survival (OS), and their associated factors were evaluated.The 5-year RFS in the full cohort of 896 patients was 82.4%, and the OS was 85.3%. In patients with initial Organ Procurement and Transplantation Network (OPTN) T1 and T2, the 5-year RFS and OS did not significantly differ between LT groups with and without bridging (all p ≥ 0.05). The 5-year RFS and OS of OPTN T3 patients with successful downstaging were not significantly different from those of patients with OPTN T2 with primary LT (p = 0.070 and p = 0.185), but were significantly higher than in patients with OPTN T3 with downstaging failure and initial OPTN T1 or T2 with progression (all p < 0.001). In the multivariate analysis, last alpha-fetoprotein before LT ≥70 ng/mL (hazard ratio [HR]: 1.77, p = 0.001; HR: 1.72, p = 0.004), pretransplant HCC status exceeding the Milan criteria (HR: 5.12, p < 0.001; HR: 3.31, p < 0.001), and positron emission tomography positivity (HR: 2.57, p < 0.001; HR: 2.57, p < 0.001) were independent predictors for worse RFS and OS.The impact of bridging therapy on survival outcomes is limited in patients with early-stage HCC, whereas OPTN T1 or T2 with progression provides worse prognosis. OPTN T3 should undergo LT after successful downstaging, and OPTN T3 with successful downstaging allows for acceptable long-term posttransplant outcomes.